ARA-290 (Cibinetide): Non-Erythropoietic Tissue Protection, Innate Repair Receptor (IRR) Activation, and Neuropathy Models
A molecular study of the erythropoietin-derived peptide ARA-290 (Cibinetide). Selective activation of the Innate Repair Receptor (EPOR/CD131), suppression of microglial activation, and nerve regeneration. ARA-290 (Cibinetide) is an 11-amino-acid peptide engineered from the non-erythropoietic B-helix of erythropoietin (EPO).
- ARA-290 (Cibinetide) is an 11-amino-acid peptide engineered from the non-erythropoietic B-helix of erythropoietin (EPO).
- Selectively binds the Innate Repair Receptor (IRR), a heterodimer composed of EPOR and the common beta receptor (CD131).
- Does not bind the classical EPOR homodimer, eliminating risks of erythropoiesis, polycythemia, or thrombosis.
- Demonstrates potent anti-inflammatory and neuroprotective activity in models of small fiber neuropathy and tissue ischemia.
| CAS Registry Number | 1208110-38-6 |
|---|---|
| Molecular Formula | C51H84N16O21 |
| Molecular Mass | 1257.32 g/mol |
| Primary Biological Target | Innate Repair Receptor (EPOR/CD131 Heterodimer) |
| Analytical Purity Standard | ≥99.0% (RP-HPLC, C18, 214/220 nm) |
| Identity Verification | ESI-MS (±0.1 Da) + Karl Fischer Moisture (<3.0%) |
| Lyophilized Storage | -20°C desiccated, protected from UV light (24–36 months) |
| Reconstituted Storage | 2°C–8°C refrigerated (up to 28 days in 0.9% BA BAC water) |
1. Sequence Design: The B-Helix of Erythropoietin
Recombinant human erythropoietin (EPO) exhibits tissue-protective and neuroregenerative properties, but its therapeutic research use is constrained by its primary hematological effect: stimulating red blood cell production via the EPOR homodimer. ARA-290 (Cibinetide, sequence: H-Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH, MW 1257.32 Da) was synthesized by isolating the 11-amino-acid linear sequence corresponding to the aqueous-exposed surface of EPO's Helix B, retaining tissue repair activity while completely decoupling from erythropoiesis.
2. Selective Innate Repair Receptor (IRR) Signaling
The Innate Repair Receptor (IRR) is a heteromeric receptor complex consisting of one erythropoietin receptor (EPOR) subunit and one common beta chain (CD131 / beta-c) subunit. The IRR is transiently expressed by metabolically stressed endothelial cells, neurons, Schwann cells, and macrophages following injury. ARA-290 binds the IRR with nanomolar affinity, triggering anti-apoptotic and anti-inflammatory signaling cascades without cross-reacting with the classical (EPOR)2 homodimer.
3. Neuroprotection and Microglial Inactivation
In rodent models of small fiber neuropathy (SFN) and diabetic neurodegeneration, ARA-290 administration inhibits spinal microglial p38 MAPK phosphorylation and suppresses pro-inflammatory cytokine secretion (TNF-alpha, IL-1beta). This leads to increased intraepidermal nerve fiber density (IENFD) and axonal sprouting in dermal punch biopsy assays.
4. Laboratory Preparation and Stability
ARA-290 is a hydrophilic peptide readily soluble in sterile Bacteriostatic Water and standard phosphate-buffered saline (PBS, pH 7.2–7.4). Store lyophilized powder at -20°C in an airtight container protected from humidity. Reconstituted solutions should be stored at 2°C to 8°C and used within 28 days.
5. Bench Preparation & Assay Reproducibility for ARA-290 (Cibinetide)
When designing in-vitro experiments targeting Innate Repair Receptor (EPOR/CD131 Heterodimer), normalize dosing across replicates by molar concentration (µM or nM) using the published molecular weight (1257.32 g/mol) and batch counterion composition rather than gross powder weight alone. Log lot numbers, diluent pH, and aliquot dates to ensure batch-to-batch reproducibility across longitudinal experiments.
Peer-Reviewed References & Analytical Standards
- Brines M. et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences, 105(31), 10925–10930. [PMID: 18676614 ↗]
- Swartjes M. et al. (2011). ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain. Anesthesiology, 115(5), 1084–1092. [PMID: 21952254 ↗]
Referenced Laboratory Research Reagents
Batch-verified SwissLab catalog entries cited in this monograph
All analytical monographs and chemical data are published strictly for in-vitro laboratory research and scientific reference. Reagents must be handled by qualified personnel wearing appropriate PPE. Not for human or veterinary use.